Cargando…

BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway

BACKGROUND: The large-conductance, voltage-gated, calcium (Ca (2+))-activated potassium channel (BKCa) plays an important role in regulating Ca (2+) signaling and cell physiological function, and is aberrantly expressed in some types of cancers. The present study focuses on identifying the oncogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fenfen, Chen, Qin, Huang, Genping, Guo, Xuedong, Li, Na, Li, Yang, Li, Baohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240221/
https://www.ncbi.nlm.nih.gov/pubmed/30445932
http://dx.doi.org/10.1186/s12885-018-5027-9
_version_ 1783371598989885440
author Wang, Fenfen
Chen, Qin
Huang, Genping
Guo, Xuedong
Li, Na
Li, Yang
Li, Baohua
author_facet Wang, Fenfen
Chen, Qin
Huang, Genping
Guo, Xuedong
Li, Na
Li, Yang
Li, Baohua
author_sort Wang, Fenfen
collection PubMed
description BACKGROUND: The large-conductance, voltage-gated, calcium (Ca (2+))-activated potassium channel (BKCa) plays an important role in regulating Ca (2+) signaling and cell physiological function, and is aberrantly expressed in some types of cancers. The present study focuses on identifying the oncogenic potential and clinical significance of BKCa in endometrial adenocarcinoma, as well as exploring the mechanistic relevance by 17β -estradiol (E2) inducing aberrant activation of MEK1/2 and ERK1/2 via BKCa. METHODS: The expression of BKCa, ERK1/2 and p-ERK1/2 were examined by immunohistochemical staining in 263 cases, including 185 primary types I endometrial cancer tissues, 38 atypical endometrial hyperplasia tissues and 40 normal endometrium tissues. Cell growth, cycle, apoptosis rate, migration and invasion was separately tested in Ishikawa cells using siRNA-BKCa and/or E2 treatment, as well as the expression of these interested proteins by western blot analysis. RESULTS: We showed that expression of BKCa is significantly elevated in 185 types I endometrial adenocarcinoma tissues compared to those of the normal endometrium and atypical endometrial hyperplasia tissues. Furthermore, in vitro observations revealed that down-regulation of BKCa expression inhibited cell growth by both enhancing apoptosis and blocking G1/S transition, suppressed cell migration and invasion in Ishakiwa cells, and decreased the expression of p-MEK1/2 and p-ERK1/2. Additionally, RNAi-mediated knockdown of BKCa attenuated the increased cellular growth and invasion, as well as the elevated expression of p-MEK1/2 and p-ERK1/2 proteins, induced by E2 stimulation. More importantly, the aberrant expression of BKCa and p-ERK1/2 were closely related with poor prognostic factors in type I endometrial cancer, and up-regulated expression of p-ERK1/2 was significantly associated with shorter disease-free survival (DFS) and overall survival (OS) and was an independent prognostic factor in type I endometrial cancer patients. CONCLUSION: Our results demonstrated that BKCa and the key downstream effectors p-ERK1/2 could be involved in important signaling pathways in initiation and development of endometrial adenocarcinoma and may provide a new therapeutic approach for women with endometrial cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5027-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6240221
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62402212018-11-26 BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway Wang, Fenfen Chen, Qin Huang, Genping Guo, Xuedong Li, Na Li, Yang Li, Baohua BMC Cancer Research Article BACKGROUND: The large-conductance, voltage-gated, calcium (Ca (2+))-activated potassium channel (BKCa) plays an important role in regulating Ca (2+) signaling and cell physiological function, and is aberrantly expressed in some types of cancers. The present study focuses on identifying the oncogenic potential and clinical significance of BKCa in endometrial adenocarcinoma, as well as exploring the mechanistic relevance by 17β -estradiol (E2) inducing aberrant activation of MEK1/2 and ERK1/2 via BKCa. METHODS: The expression of BKCa, ERK1/2 and p-ERK1/2 were examined by immunohistochemical staining in 263 cases, including 185 primary types I endometrial cancer tissues, 38 atypical endometrial hyperplasia tissues and 40 normal endometrium tissues. Cell growth, cycle, apoptosis rate, migration and invasion was separately tested in Ishikawa cells using siRNA-BKCa and/or E2 treatment, as well as the expression of these interested proteins by western blot analysis. RESULTS: We showed that expression of BKCa is significantly elevated in 185 types I endometrial adenocarcinoma tissues compared to those of the normal endometrium and atypical endometrial hyperplasia tissues. Furthermore, in vitro observations revealed that down-regulation of BKCa expression inhibited cell growth by both enhancing apoptosis and blocking G1/S transition, suppressed cell migration and invasion in Ishakiwa cells, and decreased the expression of p-MEK1/2 and p-ERK1/2. Additionally, RNAi-mediated knockdown of BKCa attenuated the increased cellular growth and invasion, as well as the elevated expression of p-MEK1/2 and p-ERK1/2 proteins, induced by E2 stimulation. More importantly, the aberrant expression of BKCa and p-ERK1/2 were closely related with poor prognostic factors in type I endometrial cancer, and up-regulated expression of p-ERK1/2 was significantly associated with shorter disease-free survival (DFS) and overall survival (OS) and was an independent prognostic factor in type I endometrial cancer patients. CONCLUSION: Our results demonstrated that BKCa and the key downstream effectors p-ERK1/2 could be involved in important signaling pathways in initiation and development of endometrial adenocarcinoma and may provide a new therapeutic approach for women with endometrial cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5027-9) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-16 /pmc/articles/PMC6240221/ /pubmed/30445932 http://dx.doi.org/10.1186/s12885-018-5027-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wang, Fenfen
Chen, Qin
Huang, Genping
Guo, Xuedong
Li, Na
Li, Yang
Li, Baohua
BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
title BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
title_full BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
title_fullStr BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
title_full_unstemmed BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
title_short BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway
title_sort bkca participates in e2 inducing endometrial adenocarcinoma by activating mek/erk pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240221/
https://www.ncbi.nlm.nih.gov/pubmed/30445932
http://dx.doi.org/10.1186/s12885-018-5027-9
work_keys_str_mv AT wangfenfen bkcaparticipatesine2inducingendometrialadenocarcinomabyactivatingmekerkpathway
AT chenqin bkcaparticipatesine2inducingendometrialadenocarcinomabyactivatingmekerkpathway
AT huanggenping bkcaparticipatesine2inducingendometrialadenocarcinomabyactivatingmekerkpathway
AT guoxuedong bkcaparticipatesine2inducingendometrialadenocarcinomabyactivatingmekerkpathway
AT lina bkcaparticipatesine2inducingendometrialadenocarcinomabyactivatingmekerkpathway
AT liyang bkcaparticipatesine2inducingendometrialadenocarcinomabyactivatingmekerkpathway
AT libaohua bkcaparticipatesine2inducingendometrialadenocarcinomabyactivatingmekerkpathway